Resource Type

Journal Article 906

Conference Videos 18

Conference Information 1

Year

2024 1

2023 75

2022 87

2021 88

2020 59

2019 65

2018 57

2017 54

2016 38

2015 62

2014 40

2013 37

2012 31

2011 35

2010 33

2009 34

2008 27

2007 30

2006 9

2005 4

open ︾

Keywords

cancer 27

lung cancer 16

fuel cell 13

immunotherapy 12

breast cancer 8

cervical cancer 8

cancer therapy 7

targeted therapy 7

hepatocellular carcinoma 6

solar cell 6

COVID-19 5

Cancer 5

hematopoietic stem cell transplantation 5

hydrogen energy 5

prognosis 5

stem cell 5

Colorectal cancer 4

apoptosis 4

cell proliferation 4

open ︾

Search scope:

排序： Display mode:

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 18-42 doi: 10.1007/s11684-022-0976-4

Abstract: With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC), expanding

Keywords： non-small cell lung cancer     driver mutations     treatment strategy     resistant mechanism     immune-checkpoint    

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: Lung cancer is one of the most common human cancers and the number one cancer killer in the United StatesIn general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), but NSCLC accounts for approximately 90% of lung cancer.tools, which can improve current early detection to reduce mortality from lung cancer, do not exist.These molecular markers in NSCLC demonstrated close associations with the development of lung cancer

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer

Min ZHU, Xiang-Ning FU, Xiao-Ping CHEN

Frontiers of Medicine 2011, Volume 5, Issue 1,   Pages 53-60 doi: 10.1007/s11684-011-0121-2

Abstract: cancer.However, there is still much debate on the role of VATS in lobectomy for the treatment of lung cancercancer.this paper, we review the development of thoracoscopy, the present status of VATS for early stage of non-smallcell lung cancer (NSCLC), and comparison between VATS and open thoracotomy in the management of NSCLC

Keywords： non-small cell lung cancer     video-assisted thoracoscopic surgery     lobectomy    

HTML PDF Collect

Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters

Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 41-44 doi: 10.1007/s11684-009-0009-6

Abstract: This study aims to research the expression of spleen tyrosine kinase (Syk) in non-small cell lung cancerImmunohistochemistry was applied to detect the expression of Syk and p53 protein in 39 cases of NSCLC (23 cases of lungsquamous cell cancer, 16 cases of lung adenocarcinoma) and tumor-surrounding normal lung tissues.The positive rate of Syk was 46.15% (18/39) and 100% (39/39) in NSCLC and tumor-surrounding normal lungThe expression level of Syk in NSCLC was significantly lower than that in tumor-surrounding normal lung

Keywords： Syk kinase     carcinoma     non-small-cell lung     tumor suppressor protein p53    

HTML PDF Collect

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 105-118 doi: 10.1007/s11684-022-0934-1

Abstract: receptor (EGFR) inhibitor osimertinib (OSI) has been approved as the first-line treatment for EGFR-mutant non-smallcell lung cancer (NSCLC).exposure of “eat me” signal calreticulin and reduced the expression of immune-inhibitory receptor PD-L1 in cancercells, which might contribute to the increased phagocytosis on cancer cells pretreated with OSI.

Keywords： osimertinib     anti-CD47 antibody     combination strategy     ADCP     EGFR    

HTML PDF Collect

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line

Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale

Frontiers of Medicine 2013, Volume 7, Issue 4,   Pages 462-476 doi: 10.1007/s11684-013-0270-6

Abstract: become crucial for developing more effective therapies that target highly tumorigenic and drug-resistant cancerstem cell (CSC) populations.In this study, we demonstrate that a subset of cancer cells with CSC properties may be enriched intotumor spheroids under stem cell conditions from a non-small cell lung cancer cell line.00477736 enhances the anti-proliferative effect of gemcitabine against both the parental and the CSC-like cell

Keywords： drug resistance     cancer stem cell     checkpoint kinase 1 (CHK1)     PF-00477736     lung cancer     tumorigenicity    

HTML PDF Collect

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 157-171 doi: 10.1007/s11684-013-0272-4

Abstract:

Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant

Keywords： non-small-cell lung cancer     molecular typing     individualized medicine     molecular-targeted therapy     gene expression    

HTML PDF Collect

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 610-617 doi: 10.1007/s11684-021-0827-8

Abstract: anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous

Keywords： bevacizumab     elderly patient     advanced non-small-cell lung cancer     overall survival     toxicity    

HTML PDF Collect

Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-celllung cancer

Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu

Frontiers of Medicine 2020, Volume 14, Issue 1,   Pages 60-67 doi: 10.1007/s11684-019-0694-8

Abstract: Moreover, C620-0696 was cytotoxic in BPTF with a high expression of non-small-cell lung cancer (NSCLCpartially inhibited the migration and colony formation of NSCLC cells owing to apoptosis induction and cellpresents an effective strategy to target a bromodomain factor-mediated tumorigenesis in cancers with small

Keywords： BPTF     small molecule     epigenetics     non-small-cell lung cancer    

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

Orlistat induces ferroptosis-like cell death of lung cancer cells

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 922-932 doi: 10.1007/s11684-020-0804-7

Abstract: synthesis is involved in the progression and treatment resistance of many types of cancers, including lungcancer; however, targeting the lipogenetic pathways for cancer therapy remains an unmet clinical need, and we found that orlistat, as a single agent, inhibited the proliferation and viabilities of lungcancer cells and induced ferroptosis-like cell death in vitro.cancer and other types of cancer.

Keywords： orlistat     ferroptosis     FAF2     lung cancer    

HTML PDF Collect

Tanshinone IIA Suppresses Non-Small Cell Lung Cancer Through Beclin-1-Mediated Autophagic Apoptosis Article

Shasha Bai, Sainan Cui, Wenhao Wen, Elaine Lai-Han Leung, Jing Bai, Huiyuan Lin, Yongfei Cui, Lei Yang, Zhongqiu Liu, Yuan Zheng, Rong Zhang

Engineering 2022, Volume 19, Issue 12,   Pages 128-138 doi: 10.1016/j.eng.2021.07.014

Abstract:

It is necessary to develop a new strategy for treatment of lung cancer since it is the main causeof cancer death.It has been found that Tan IIA could inhibit lung cancer in vitro and in vivo by inducinglymphoma-2 (Bcl-2)/Bcl-2 associated X protein (Bax) ratio in human non-small cell lung cancer (NSCLC) cell lines, which was promoted by an autophagy activator Rapamycin, and weaken by autophagy inhibitor

Keywords： Tan IIA     Autophagy     Apoptosis     Beclin-1    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract:

Lung cancer is the most common incident cancer and the leading cause of cancer death.EGFRvIII) is a tumor-specific mutation expressed in various types of tumors and has been detected in non-smallcell lung cancer with a mutation rate of 10%.Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy.EGFRvIII-CART showed significantly efficient antitumor activity against lung cancer cells expressing

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Genomic variations in the counterpart normal controls of lung squamous cell carcinomas

Dalin Zhang, Liwei Qu, Bo Zhou, Guizhen Wang, Guangbiao Zhou

Frontiers of Medicine 2018, Volume 12, Issue 3,   Pages 280-288 doi: 10.1007/s11684-017-0580-1

Abstract:

Lung squamous cell carcinoma (LUSC) causes approximately 400 000 deaths each year worldwide.squamous cell carcinomas.of the normal lung tissues against that of the paired tumors, the reference human genome, the dbSNP138observations, the whole exome sequences of 478 counterpart normal controls (CNCs) and paired LUSCs of The CancerSixteen genomic variations were called in the three normal lung tissues.

Keywords： lung cancer     counterpart normal control     genomic variations    

HTML PDF Collect

The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China

Yize Xiao, Ying Shao, Xianjun Yu, Guangbiao Zhou

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 388-394 doi: 10.1007/s11684-012-0233-3

Abstract: Unfortunately, the lung cancer morbidity and mortality rates in this region are among China’s highestIn 2004–2005, the crude death rate of lung cancer was 91.3 per 100 000 in the whole Xuanwei CityThe epidemiologic distribution (clustering patterns by population, time, and space) of lung cancer inThe main factor that associates with a high rate of lung cancer incidence was found to be indoor airthe key to diminish lung cancer morbidity and mortality.

Keywords： lung cancer     Xuanwei     smoky coal combustion     polycyclic aromatic hydrocarbons     epidemiology    

HTML PDF Collect

Title Author Date Type Operation

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer

Min ZHU, Xiang-Ning FU, Xiao-Ping CHEN

Journal Article

Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters

Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU

Journal Article

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Journal Article

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line

Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale

Journal Article

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Journal Article

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis

Journal Article

Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-celllung cancer

Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu

Journal Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article

Orlistat induces ferroptosis-like cell death of lung cancer cells

Journal Article

Tanshinone IIA Suppresses Non-Small Cell Lung Cancer Through Beclin-1-Mediated Autophagic Apoptosis

Shasha Bai, Sainan Cui, Wenhao Wen, Elaine Lai-Han Leung, Jing Bai, Huiyuan Lin, Yongfei Cui, Lei Yang, Zhongqiu Liu, Yuan Zheng, Rong Zhang

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Genomic variations in the counterpart normal controls of lung squamous cell carcinomas

Dalin Zhang, Liwei Qu, Bo Zhou, Guizhen Wang, Guangbiao Zhou

Journal Article

The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China

Yize Xiao, Ying Shao, Xianjun Yu, Guangbiao Zhou

Journal Article